Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 61.44% | 30.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 61.44% | 30.21% | |||
| Cost of Revenue | 40.01% | 101.23% | |||
| Gross Profit | 66.29% | 20.57% | |||
| SG&A Expenses | -0.38% | 34.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.54% | 37.11% | |||
| Operating Income | 2,371.63% | -189.61% | |||
| Income Before Tax | 775.86% | 15.00% | |||
| Income Tax Expenses | -139.18% | 94.67% | |||
| Earnings from Continuing Operations | 478.84% | -15.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 478.84% | -15.31% | |||
| EBIT | 2,371.63% | -189.61% | |||
| EBITDA | 17,030.60% | -106.94% | |||
| EPS Basic | 476.47% | -14.46% | |||
| Normalized Basic EPS | 912.78% | 16.95% | |||
| EPS Diluted | 462.63% | -14.46% | |||
| Normalized Diluted EPS | 877.87% | 16.95% | |||
| Average Basic Shares Outstanding | 0.63% | 0.73% | |||
| Average Diluted Shares Outstanding | 5.14% | 0.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||